Decoding Deprescribing: Strategies and Approaches for Rational Medication Reduction

October 28th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.

June 30th 2023

Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Oral Semaglutide Wins FDA Approval to Reduce Risk of MACE in Adults with T2D at High Risk

October 20th 2025

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

July 22nd 2022

Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.

Mazdutide Demonstrates Superior Glycemic Control and Weight Loss vs Semaglutide in Head-to-Head Trial

Topline phase 3 data shows oral GLP-1 cuts HbA1c by 2.1% when added to basal insulin, nearly triple placebo's effect in patients poorly controlled on current therapy.

Related Content

October 28th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

The phase 3 DREAMS-3 trial is the fist phase 3 head-to-head comparison of a GLP-1/glucagon dual receptor agonist against semaglutide in diabetes treatment.

June 30th 2023

Oral Semaglutide Wins Approval to Reduce Risk of MACE in Adults with T2D at High Risk

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

October 20th 2025

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

July 22nd 2022

Three GLP-1 Receptor Agonists Show Comparable Cardiorenal Protection in Large US Cohort with T2D

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Lilly's Novel Oral GLP-1 Orforglipron Shows Superior Efficacy in 2 Phase 3 Trials

GLP-1 RAs liraglutide, semaglutide, and dulaglutide showed similar kidney and cardiovascular outcomes more than 20,000 US veterans with type 2 diabetes.